March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Complement Mediated Retinal Pericyte Injury
Author Affiliations & Notes
  • Feng Lin
    Pathology,
    Case Westersn Reserve Univ, Cleveland, Ohio
  • Dawn Smith
    Ophthalmology,
    Case Westersn Reserve Univ, Cleveland, Ohio
  • Qing Li
    Pathology,
    Case Westersn Reserve Univ, Cleveland, Ohio
  • Ram Nagaraj
    Ophthalmology,
    Case Westersn Reserve Univ, Cleveland, Ohio
  • Timothy Kern
    Medicine,
    Case Westersn Reserve Univ, Cleveland, Ohio
  • Yan Li
    Pathology,
    Case Westersn Reserve Univ, Cleveland, Ohio
  • Footnotes
    Commercial Relationships  Feng Lin, None; Dawn Smith, None; Qing Li, None; Ram Nagaraj, None; Timothy Kern, None; Yan Li, None
  • Footnotes
    Support  EY020956
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 2412. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Feng Lin, Dawn Smith, Qing Li, Ram Nagaraj, Timothy Kern, Yan Li; Complement Mediated Retinal Pericyte Injury. Invest. Ophthalmol. Vis. Sci. 2012;53(14):2412.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Loss of retinal pericytes is a hallmark of early stage diabetic retinopathy, but the mechanisms underlying retinal pericytes loss in diabetes are unclear. Our purpose was to test the hypotheses that complement activated by retinal pericyte-reactive autoantibodies leads to retinal pericytes cytotoxicity, and that inhibiting complement activation by upregulating endogenous cell surface complement regulators or by administering exogenous complement inhibitors is a novel approach to protect retinal pericytes from autoantibodies-induced injury, and to prevent the development of diabetic retinopathy

Methods: : Human primary retinal pericytes were cultured in media containing normal and high levels of glucose, then incubated with human sera in the presence of a retinal pericyte-reactive antibody. Complement-mediated cellular injury was assessed by a conventional BCECF leakage-based cytotoxicity assay. The presence of intrinsic cell surface complement regulators on retinal pericytes was determined by flow cytometry. The presence of CD38, a diabetes-associated cell surface autoantigen, on retinal pericytes was examined by RT-PCR and flow cytometry. To test the effectiveness of inhibiting complement activation for protecting retinal pericytes, a CD55-expressing recombinant adenovirus was constructed and used to transfect retinal pericytes, and an anti-C5 IgG was employed to inhibit membrane attack complex (MAC) formation in the same cytotoxicity assays.

Results: : In the presence of a retinal pericyte-reactive antibody, retinal pericytes were injured by complement despite the presence of all three intrinsic cell surface complement regulators, i.e., CD55, CD46 and CD59. CD38 was expressed by primary retinal pericytes, and upregulated by TNFα/IFNγ, inflammatory cytokines that are associated with the development of diabetic retinopathy. Hyperglycemic culture conditions rendered retinal pericytes more susceptible to complement mediated attack with minimal effects on expression levels of the cell surface complement inhibitors. Upregulating CD55 expression levels on retinal pericytes, or inhibiting MAC formation by an anti-C5 antibody protected retinal pericytes from the autoantibodies-induced cellular injury.

Conclusions: : The autoantibody- activated complement could be a mechanism underlying the loss of retinal pericytes in diabetic patients. Inhibiting complement activation by upregulating levels of intrinsic cell surface complement inhibitors, or by administering exogenous complement inhibitors, could reduce the loss of retinal pericytes, and help to prevent the development of diabetic retinopathy.

Keywords: diabetic retinopathy • inflammation • immunomodulation/immunoregulation 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×